Sanofi Reports Strong Q3 Profit Surge, Raises Full-Year Guidance and Accelerates Drug Development Pipeline

Intelligent Finance APP learned that the third-quarter profit of French pharmaceutical giant Sanofi (SNY.US) increased due to the growth of seasonal vaccine demand and the strong performance of its blockbuster drug Dupixent. The earnings report shows that the company's earnings per share in the third quarter reached 2.86 euros, surpassing analysts' expectations, mainly due to the early sales of flu and respiratory syncytial virus vaccines. Sanofi's net profit increased from 2.53 billion euros in the same period last year to 2.82 billion euros. Sanofi has raised its guidance for business earnings per share in 2024 to achieve at least a low single-digit percentage increase, excluding the soon-to-be-sold consumer health division Opella.

The company expects that currency fluctuations will have a negative impact of -5.5% to -6.5% on business earnings per share in 2024. In addition, Sanofi is in exclusive negotiations with U.S. acquisition firm Clayton Dubilier & Rice for the sale of its consumer health division and has raised its annual profit forecast.

Sanofi CEO Paul Hudson is accelerating Sanofi's drug development plans, particularly driving the sales of drugs like Dupixent, which saw a 24% increase in sales this quarter, reaching approximately €3.5 billion.

Moreover, Sanofi is advancing more than a dozen potential blockbuster drugs through clinical trials, a strategy similar to that of competitors like Novartis, focusing on cutting-edge therapies while divesting older drugs and consumer health divisions.

The growth in the vaccine business was partly driven by the newly launched Beyfortus vaccine, which protects infants from respiratory syncytial virus infection.

Sanofi CFO François-Xavier Roger expressed optimism about the competition with Merck's respiratory syncytial virus monoclonal antibody vaccine, stating that Sanofi’s vaccine demonstrates higher efficacy and evidence already shows it provides protection for tens of thousands of infants.

In recent weeks, the focus for Sanofi has been the sale of its consumer health business, Opella. Roger stated that this move would provide "a huge opportunity" for the division to operate independently and allow Sanofi to become a pure biopharmaceutical company.